CN102775368B - 一类噻唑类化合物及其制备方法和用途 - Google Patents
一类噻唑类化合物及其制备方法和用途 Download PDFInfo
- Publication number
- CN102775368B CN102775368B CN201110120207.9A CN201110120207A CN102775368B CN 102775368 B CN102775368 B CN 102775368B CN 201110120207 A CN201110120207 A CN 201110120207A CN 102775368 B CN102775368 B CN 102775368B
- Authority
- CN
- China
- Prior art keywords
- compound
- aryl
- alkyl
- thiazole
- thiazole compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 0 Cc1c(C)[s]c(-c2nc(C(***)=O)c(*)[s]2)c1* Chemical compound Cc1c(C)[s]c(-c2nc(C(***)=O)c(*)[s]2)c1* 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/58—Nitro radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims (6)
Priority Applications (11)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110120207.9A CN102775368B (zh) | 2011-05-10 | 2011-05-10 | 一类噻唑类化合物及其制备方法和用途 |
US14/116,944 US9216962B2 (en) | 2011-05-10 | 2012-05-07 | Thiazole compounds, methods for preparation and use thereof |
EP12781747.6A EP2708534B1 (en) | 2011-05-10 | 2012-05-07 | Thiazole compound and preparation method and use thereof |
JP2014509592A JP6236382B2 (ja) | 2011-05-10 | 2012-05-07 | チアゾール系化合物、その調製方法及び用途 |
NZ617505A NZ617505B2 (en) | 2011-05-10 | 2012-05-07 | Thiazole compound and preparation method and use thereof |
CA2835705A CA2835705C (en) | 2011-05-10 | 2012-05-07 | Thiazole compounds, methods for preparation and use thereof |
AU2012253019A AU2012253019B2 (en) | 2011-05-10 | 2012-05-07 | Thiazole compound and preparation method and use thereof |
BR112013028894-9A BR112013028894B1 (pt) | 2011-05-10 | 2012-05-07 | Compostos de tiazol, métodos para preparação e uso do mesmo |
KR1020137031882A KR101577520B1 (ko) | 2011-05-10 | 2012-05-07 | 티아졸계 화합물 및 그 제조 방법 |
PCT/CN2012/075142 WO2012152208A1 (zh) | 2011-05-10 | 2012-05-07 | 一类噻唑类化合物及其制备方法和用途 |
MX2013013048A MX343540B (es) | 2011-05-10 | 2012-05-07 | Compuesto de tiazol y metodo de preparacion y uso del mismo. |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201110120207.9A CN102775368B (zh) | 2011-05-10 | 2011-05-10 | 一类噻唑类化合物及其制备方法和用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102775368A CN102775368A (zh) | 2012-11-14 |
CN102775368B true CN102775368B (zh) | 2016-08-17 |
Family
ID=47120501
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201110120207.9A Active CN102775368B (zh) | 2011-05-10 | 2011-05-10 | 一类噻唑类化合物及其制备方法和用途 |
Country Status (10)
Country | Link |
---|---|
US (1) | US9216962B2 (zh) |
EP (1) | EP2708534B1 (zh) |
JP (1) | JP6236382B2 (zh) |
KR (1) | KR101577520B1 (zh) |
CN (1) | CN102775368B (zh) |
AU (1) | AU2012253019B2 (zh) |
BR (1) | BR112013028894B1 (zh) |
CA (1) | CA2835705C (zh) |
MX (1) | MX343540B (zh) |
WO (1) | WO2012152208A1 (zh) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2014236711A1 (en) * | 2013-03-14 | 2015-09-17 | Celgene Quanticel Research, Inc. | Histone demethylase inhibitors |
CN104974108B (zh) * | 2014-04-04 | 2017-11-17 | 中国科学院上海药物研究所 | 一类2,2’‑串联双噻唑类化合物及其制备方法和用途 |
CN106535891A (zh) * | 2014-06-02 | 2017-03-22 | Chdi基金会股份有限公司 | 组蛋白脱乙酰酶抑制剂及其组合物和使用方法 |
CN105315226A (zh) * | 2014-07-11 | 2016-02-10 | 中国科学院生态环境研究中心 | 一种以羧酸为底物一锅法合成2,4-二取代噻唑的新方法 |
US11420950B2 (en) | 2015-05-22 | 2022-08-23 | Chong Kun Dang Pharmaceutical Corp. | Heterocyclicalkyl derivative compounds as selective histone deacetylase inhibitors and pharmaceutical compositions comprising the same |
CN107793375A (zh) * | 2016-08-31 | 2018-03-13 | 中国科学院上海药物研究所 | 一类芳基2,2’‑串联双噻唑类化合物及其制备方法和用途 |
Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002026696A1 (en) * | 2000-09-29 | 2002-04-04 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
CN1378450A (zh) * | 1999-09-08 | 2002-11-06 | 斯隆-凯特林癌症研究院 | 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法 |
US20050014839A1 (en) * | 2003-07-07 | 2005-01-20 | Kozikowski Alan P. | Histone deacetylase inhibitors and methods of use thereof |
US20060079551A1 (en) * | 2001-10-16 | 2006-04-13 | Richon Victoria M | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
CN1768031A (zh) * | 2003-04-07 | 2006-05-03 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
CN1834095A (zh) * | 2005-03-18 | 2006-09-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
WO2006097460A1 (en) * | 2005-03-15 | 2006-09-21 | Menarini International Operations Luxembourg S.A. | Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them |
CN101001851A (zh) * | 2004-08-09 | 2007-07-18 | 安斯泰来制药有限公司 | 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物 |
US20070167499A1 (en) * | 2003-10-27 | 2007-07-19 | A*Bio Pte Ltd. | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
CN101035542A (zh) * | 2004-08-25 | 2007-09-12 | 默克公司 | 组蛋白脱乙酰基酶抑制剂 |
CN101048374A (zh) * | 2004-09-02 | 2007-10-03 | Osi制药公司 | 作为组蛋白脱乙酰酶抑制剂的巯基酰胺 |
WO2008019025A2 (en) * | 2006-08-03 | 2008-02-14 | Georgetown University | Isoform-selective hdac inhibitors |
US20090069391A1 (en) * | 2005-04-20 | 2009-03-12 | Jed Lee Hubbs | Benzothiophene hydroxamic acid derivatives |
CN101679239A (zh) * | 2007-03-13 | 2010-03-24 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
CN101918389A (zh) * | 2007-11-02 | 2010-12-15 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2003070691A1 (fr) * | 2002-02-21 | 2003-08-28 | Osaka Industrial Promotion Organization | Derive de n-hydroxycarboxamide |
EP1644323B1 (en) * | 2003-07-07 | 2015-03-18 | Georgetown University | Histone deacetylase inhibitors and methods of use thereof |
MXPA05011286A (es) * | 2003-08-20 | 2006-01-24 | Axys Pharm Inc | Derivados de acetileno como inhibidores de histona deacetilasa. |
WO2010028192A1 (en) * | 2008-09-03 | 2010-03-11 | Repligen Corporation | Compositions including 6-aminohexanoic acid derivatives as hdac inhibitors |
-
2011
- 2011-05-10 CN CN201110120207.9A patent/CN102775368B/zh active Active
-
2012
- 2012-05-07 AU AU2012253019A patent/AU2012253019B2/en active Active
- 2012-05-07 JP JP2014509592A patent/JP6236382B2/ja active Active
- 2012-05-07 KR KR1020137031882A patent/KR101577520B1/ko active IP Right Grant
- 2012-05-07 BR BR112013028894-9A patent/BR112013028894B1/pt active IP Right Grant
- 2012-05-07 CA CA2835705A patent/CA2835705C/en active Active
- 2012-05-07 EP EP12781747.6A patent/EP2708534B1/en active Active
- 2012-05-07 US US14/116,944 patent/US9216962B2/en active Active
- 2012-05-07 MX MX2013013048A patent/MX343540B/es active IP Right Grant
- 2012-05-07 WO PCT/CN2012/075142 patent/WO2012152208A1/zh active Application Filing
Patent Citations (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1378450A (zh) * | 1999-09-08 | 2002-11-06 | 斯隆-凯特林癌症研究院 | 新型细胞分化剂和组蛋白脱乙酰基酶抑制剂及其使用方法 |
WO2002026696A1 (en) * | 2000-09-29 | 2002-04-04 | Prolifix Limited | Carbamic acid compounds comprising an amide linkage as hdac inhibitors |
US20060079551A1 (en) * | 2001-10-16 | 2006-04-13 | Richon Victoria M | Treatment of neurodegenerative diseases and cancer of the brain using histone deacetylase inhibitors |
CN1768031A (zh) * | 2003-04-07 | 2006-05-03 | Axys药物公司 | 作为治疗剂的异羟肟酸酯 |
US20050014839A1 (en) * | 2003-07-07 | 2005-01-20 | Kozikowski Alan P. | Histone deacetylase inhibitors and methods of use thereof |
US20070167499A1 (en) * | 2003-10-27 | 2007-07-19 | A*Bio Pte Ltd. | Biaryl linked hydroxamates: preparation and pharmaceutical applications |
CN101001851A (zh) * | 2004-08-09 | 2007-07-18 | 安斯泰来制药有限公司 | 具有作为组蛋白脱乙酰酶(hdac)抑制剂的活性的羟基酰胺化合物 |
CN101035542A (zh) * | 2004-08-25 | 2007-09-12 | 默克公司 | 组蛋白脱乙酰基酶抑制剂 |
CN101048374A (zh) * | 2004-09-02 | 2007-10-03 | Osi制药公司 | 作为组蛋白脱乙酰酶抑制剂的巯基酰胺 |
WO2006097460A1 (en) * | 2005-03-15 | 2006-09-21 | Menarini International Operations Luxembourg S.A. | Hydroxamates as histone deacetylase inhibitors and pharmaceutical formulations containing them |
CN1834095A (zh) * | 2005-03-18 | 2006-09-20 | 中国科学院上海药物研究所 | 一类非核苷类抗病毒抑制剂及其制备方法和用途 |
US20090069391A1 (en) * | 2005-04-20 | 2009-03-12 | Jed Lee Hubbs | Benzothiophene hydroxamic acid derivatives |
WO2008019025A2 (en) * | 2006-08-03 | 2008-02-14 | Georgetown University | Isoform-selective hdac inhibitors |
CN101679239A (zh) * | 2007-03-13 | 2010-03-24 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
CN101918389A (zh) * | 2007-11-02 | 2010-12-15 | 梅特希尔基因公司 | 组蛋白脱乙酰酶抑制剂 |
Also Published As
Publication number | Publication date |
---|---|
BR112013028894A2 (pt) | 2016-09-06 |
NZ617505A (en) | 2015-11-27 |
JP2014517831A (ja) | 2014-07-24 |
JP6236382B2 (ja) | 2017-11-22 |
AU2012253019B2 (en) | 2016-03-03 |
AU2012253019A1 (en) | 2013-11-28 |
WO2012152208A1 (zh) | 2012-11-15 |
CA2835705C (en) | 2016-01-19 |
KR101577520B1 (ko) | 2015-12-14 |
US20140148600A1 (en) | 2014-05-29 |
EP2708534A4 (en) | 2015-02-18 |
US9216962B2 (en) | 2015-12-22 |
BR112013028894B1 (pt) | 2021-06-29 |
CN102775368A (zh) | 2012-11-14 |
CA2835705A1 (en) | 2012-11-15 |
MX343540B (es) | 2016-11-08 |
EP2708534B1 (en) | 2017-07-12 |
EP2708534A1 (en) | 2014-03-19 |
MX2013013048A (es) | 2014-09-25 |
KR20140028046A (ko) | 2014-03-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102775368B (zh) | 一类噻唑类化合物及其制备方法和用途 | |
Scozzafava et al. | Carbonic anhydrase inhibitors. A general approach for the preparation of water-soluble sulfonamides incorporating polyamino− polycarboxylate tails and of their metal complexes possessing long-lasting, topical intraocular pressure-lowering properties | |
US11124486B2 (en) | 6-membered heterocyclic derivatives and pharmaceutical composition comprising the same | |
US9822058B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
BR112014030966B1 (pt) | Composto derivado de éster de ácido heteroarilcarboxílico como inibidor hiperglicêmico tendo uma ação inibitória de serina protease e como droga profilática ou terapêutica para diabetes, composição farmacêutica, e, uso do composto ou sal | |
US20120197024A1 (en) | Thiazole Compound (as PPAR delta) Ligand and Pharmaceutical, Cosmetic and Health Food Comprised Thereof | |
CN101812059B (zh) | 一氧化氮供体型法尼基硫代水杨酸衍生物、其制备方法及其医药用途 | |
CN101896068A (zh) | 抗凋亡蛋白的萘基抑制剂 | |
US10428054B2 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
US11370803B2 (en) | Heteroaryl plasma kallikrein inhibitors | |
US20210009564A1 (en) | Calpain modulators and therapeutic uses thereof | |
Tilekar et al. | Permuted 2, 4-thiazolidinedione (TZD) analogs as GLUT inhibitors and their in-vitro evaluation in leukemic cells | |
CN112047993A (zh) | 一种α-葡萄糖苷酶抑制剂及其用途 | |
CN101146804B (zh) | 用作抗癌剂的5-(1,3-二芳基-1h-吡唑-4-基亚甲基)-噻唑烷-2,4-二酮衍生物 | |
US20170224651A1 (en) | Aromatic farnesyl compound and application thereof | |
CN108137540A (zh) | 8-羟基喹啉衍生物的对映异构体及其合成 | |
US10064843B2 (en) | Bis-amide derivative and use thereof | |
TW201317229A (zh) | 稠合雜環衍生物 | |
Bytyqi-Damoni et al. | Synthesis, characterization, and computational study of novel carvacrol-based 2-aminothiol and sulfonic acid derivatives as metabolic enzyme inhibitors | |
CN102285933B (zh) | 一种对亚型过氧化物酶增殖物激活受体具有激动作用的化合物、其制备方法和应用 | |
Abdelrahim et al. | Design, synthesis, molecular modelling and biological evaluation of novel α-naphtholhydroxamate derivatives as potential anticancer agents | |
CN104926721A (zh) | 异烟肼咖啡酸酰胺化衍生物及在抗结核杆菌药物中的应用 | |
US20240092770A1 (en) | Heterocycle RMB39 Modulators | |
WO2023201014A1 (en) | Benzothiazole-phenylsulfonyl-piperidine analogs as activators of n-acylphosphatidylethanolamine hydrolyzing phospholipase d | |
CN103880793A (zh) | 含呋喃亚胺类化合物及其制备方法和用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
ASS | Succession or assignment of patent right |
Owner name: GYROCHEM (SHANGHAI PUYI) CO., LTD. Free format text: FORMER OWNER: SHANGHAI INST. OF MEDICINE, CHINESE ACADEMY OF SCIENCES Effective date: 20130118 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 201203 PUDONG NEW AREA, SHANGHAI TO: 201612 SONGJIANG, SHANGHAI |
|
TA01 | Transfer of patent application right |
Effective date of registration: 20130118 Address after: 201612 Shanghai Songjiang 201 min Yick Road No. 11 building 3 floor Applicant after: Gyrochem (Shanghai Puyi) Co., Ltd. Address before: 201203 Shanghai City, Pudong New Area Zhangjiang Zuchongzhi Road No. 555 Applicant before: Shanghai Institute of Materia Medica, Chinese Academy of Sciences |
|
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C41 | Transfer of patent application or patent right or utility model | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20160615 Address after: 201203 Shanghai city Pudong New Area Jing Road No. 351 Building No. 2 room A664-2 Applicant after: GYROCHEM (SHANGHAI PUYI) CO., LTD. Address before: 201612 Shanghai Songjiang 201 min Yick Road No. 11 building 3 floor Applicant before: Gyrochem (Shanghai Puyi) Co., Ltd. |
|
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
EE01 | Entry into force of recordation of patent licensing contract | ||
EE01 | Entry into force of recordation of patent licensing contract |
Application publication date: 20121114 Assignee: Jiangxi Longchang Pharmaceutical Co.,Ltd. Assignor: Shanghai Puyi Chemical Co.,Ltd. Contract record no.: X2021310000030 Denomination of invention: A thiazole compound and its preparation method and Application Granted publication date: 20160817 License type: Exclusive License Record date: 20210722 |